Xilio Therapeutics, Inc. Fair Value Adjustment of Warrants
Xilio Therapeutics, Inc. (XLO) reported Fair Value Adjustment of Warrants of $3.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-12
- Xilio Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was $3.94M, a 7780.00% increase year-over-year.
- Xilio Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$3.30M.
- Xilio Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$21.27M.
- Xilio Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $15.38M.
- Xilio Therapeutics, Inc. fair value adjustment of warrants for fiscal 2025 was -$5.84M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.94M 10-Q · filed 2026-08-12 | $640.00K 10-Q · filed 2026-08-12 | -$20.64M derived: sum of 3 quarters · filed 2026-08-12 | -$5.25M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$3.30M 10-Q · filed 2026-05-12 | -$24.57M derived: sum of 2 quarters · filed 2026-05-12 | -$9.20M derived: sum of 3 quarters · filed 2026-05-12 | -$9.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$21.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$5.89M derived: sum of 2 quarters · filed 2026-03-23 | -$5.84M derived: sum of 3 quarters · filed 2026-08-12 | -$5.84M 10-K · filed 2026-03-23 |
| 2025-09-30 | $15.38M 10-Q · filed 2025-11-13 | $15.43M derived: sum of 2 quarters · filed 2026-08-12 | $15.43M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $50.00K 10-Q · filed 2026-08-12 | $50.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |